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41 participants successfully established a reduced symptom profile in patients with IBS when adhering to a
diet low in FODMAPs. Lastly, a randomized, single-blinded control trial recruited both healthy patients and
those with IBS to demonstrate the success of a low FODMAP diet.
Conclusion: A diet low in fermentable sugars has demonstrated reduction of symptoms in patients with
irritable bowel syndrome. Primary care providers as well as GI specialists can educate their patients with IBS
on the diet and encourage them to adhere with little worry of cost or harm to the population. Although the
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Abstract 
 
Background: Irritable bowel syndrome (IBS) is a common disorder, affecting 7-10% of 
the worldwide population. It consists of abdominal pain and altered bowel habits present 
for at least three months. Poorly absorbed, short-chain carbohydrates are grouped based 
on chain length and result in the acronym FODMAP: fermentable oligo-, di-, mono-, and 
polyols. These FODMAPs pass through the small bowel unabsorbed and may be 
affecting symptoms in those with IBS. Does a diet low in fermentable sugars improve 
symptoms for patients with IBS? 
 
Method: An exhaustive literature search was conducted using Medline, CINAHL, and 
Google Scholar with use of keywords “FODMAP diet” and “irritable bowel syndrome.” 
Further review of bibliographies was completed for any other relevant resources. Articles 
were then assessed for quality using Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE).  
 
Results: After reviewing for relevancy, three articles met inclusion criteria.  These 
articles included three randomized control trials. A double-blinded, randomized, placebo-
controlled trial with 26 participants demonstrated reduction in symptom severity with a 
diet low in FODMAPs. A randomized control trial with 41 participants successfully 
established a reduced symptom profile in patients with IBS when adhering to a diet low 
in FODMAPs. Lastly, a randomized, single-blinded control trial recruited both healthy 
patients and those with IBS to demonstrate the success of a low FODMAP diet.  
 
Conclusion: A diet low in fermentable sugars has demonstrated reduction of symptoms 
in patients with irritable bowel syndrome.  Primary care providers as well as GI 
specialists can educate their patients with IBS on the diet and encourage them to adhere 
with little worry of cost or harm to the population.  Although the studies have limitations 
and further, stronger research is needed, the benefits of this lifestyle intervention seem to 
outweigh the risks to the patient. 
 
 
Keywords: Irritable bowel syndrome, FODMAP diet 
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The Efficacy of a Diet Low in Fermentable Sugars in the Reduction of Symptoms 
for Patients with Irritable Bowel Syndrome 
BACKGROUND 
 Irritable bowel syndrome (IBS) is a common disorder, affecting 7-10% of the 
worldwide population. It consists of abdominal pain and altered bowel habits present for 
at least three months. 1 Three components help to define the disease, and these are gut 
reactivity in response to luminal stimuli or distention that results in symptoms of diarrhea 
or constipation, increased sensitivity of the gut with increased visceral perception and 
pain, and altered regulation of the brain-gut communication possibly influenced by 
stress.2 The condition can be present as diarrhea, constipation, or alternating in 
predominance, where as the diarrhea and alternating types being the more commonly 
seen.1 Those with this condition often have worsening symptoms of abdominal pain and 
bloating following meals, leading many patients to assume a food allergy as the culprit. 
Specific diagnostic tests are lacking for the condition and patients are therefore diagnosed 
by exclusion of other disease entities and the application of symptom-based criteria. The 
diagnostic criteria most commonly utilized are that of the Rome Criteria. 3 This defines 
IBS as recurrent abdominal pain or discomfort at least 3 days per month in the last 3 
months associated with two or more of the following: improvement with defecation, 
onset associated with change in frequency of stool, and onset associated with a change in 
form of stool. 4  
IBS is 1.5 times more likely in women. It is one of the most commonly seen 
conditions by both primary care providers as well as gastrointestinal (GI) specialists and 
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therefore causes large healthcare expenses. This population is known to have more 
frequent doctor visits, more workdays missed with a resulting lower work productivity, 
and consume more medications as well as overall direct costs than those without the 
diagnosis. 1  
Current treatment options include eliminating known dietary triggers such as 
lactose or caffeine, use of medications that target the dominant symptom, cognitive 
behavioral therapy, and anti-depressants. IBS seems to be inadequately managed in the 
clinical setting, however, and this is potentially due to conventional treatment methods 
suboptimally controlling symptoms. 5  
Carbohydrates or sugars are common ingredients within daily diets across the 
world.  These dietary substances are large polysaccharides or disaccharides that must 
undergo digestion to then become absorbable monosaccharides. Active transport occurs 
within the small intestine to absorb these end products. One’s diet can influence the 
efficiency of this process and the carbohydrate load that then reaches the colon 
unabsorbed. These carbohydrates undergo fermentation by colonic bacteria and theories 
exist stating this process is important in the symptoms of bloating, abdominal distention, 
and changes in bowel habits. 6 Poorly absorbed, short-chain carbohydrates are grouped 
based on chain length and result in the acronym FODMAP: fermentable oligo-, di-, 
mono-, and polyols. 7 These FODMAPs pass through the small bowel unabsorbed and 
may be affecting symptoms in those with IBS. 6 Foods high in FODMAPs are not 
necessarily the cause of the condition but in the presence of IBS, they may bring on the 
symptoms of bloating, abdominal pain, and motility changes. 7 Common foods found to 
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be rich sources of FODMAPs include wheat, rye, onions, garlic, artichokes, legumes, 
milk, honey, apples, pears, sugar-free gums/mints, mushrooms, and cauliflower. 7 
Recent articles have suggested the reduction of symptoms with the use of a diet 
low in FODMAPs.6,7 If this is the case, the use of a diet low in FODMAPs has the 
potential to reduce the symptom severity within this population. This review will address 
the research further.  
METHODS 
 An exhaustive literature search was conducted using Medline, CINAHL, and 
Google Scholar with use of keywords “FODMAP diet” and “irritable bowel syndrome.”  
Further review of bibliographies was completed for any other relevant resources.  
Relevant randomized control trials with focused data on the efficacy of a diet low in 
fermentable sugars in patients with IBS were included.  Articles were excluded if the 
study looked at patient populations with other bowel diagnoses such as Crohn or Celiac 
disease.  Articles were then assessed for quality using Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE).  11 
RESULTS 
 The initial systematic literature search resulted in 237 articles.  After reviewing 
for relevancy, three articles met inclusion criteria.  These articles included three 
randomized control trials. 8-10 See Table 1.  
Shepherd et al 
 This double-blinded, randomized, placebo-controlled trial, 8 conducted in 
Australia, investigated the effect of fermentable sugars on symptom severity in patients 
with IBS.  The trial involved 26 participants with IBS who were recruited from a 
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hospital-based dietetic practice. The median age of participants was 38 years old, four 
participants were male, and all were Caucasian except one patient of Chinese heritage.  
Participants had varied IBS symptoms with twelve diarrhea-predominant, five 
constipation-predominant, and eight alternating bowel habits. Twelve participants were 
being treated with symptom-based medications at recruitment and these were continued 
at a stable dose throughout the study.  One participant was excluded due to withdrawal 
prior to treatment.  Primary outcomes included patient symptoms, evaluated by a global 
symptom question of “Were your symptoms adequately controlled in this phase?” and 
symptom scoring based on a visual analogue scale assessing the severity of several 
symptoms. 8 
Inclusion criteria of the study was diagnosis of IBS based on the Rome II Criteria, 
positive fructose breath hydrogen testing following a 35-gram load of fructose, 
instruction in a low FODMAP diet at least three months prior to recruitment, and 
significant improvement of GI symptoms on this diet.  Exclusion criteria included the 
diagnosis of Celiac Disease, Inflammatory Bowel Disease, or other co-morbidity. 8 
Patients were provided all food for the duration of the study. This was a diet low 
in FODMAPs for 22 weeks. The patients were tested with one of four test substances in a 
four-arm, crossover design. These substances were varying carbohydrates, given in the 
form of powder drinks, dosed three times a day with meals.  Three of the substances were 
fermentable sugars (fructan, fructose, fructan/fructose mix), all providing separate control 
arms.  The last substance contained glucose, which provided the treatment arm as this is 
not a fermentable sugar and represents a diet of low in FODMAPs.  The drinks were 
provided in phases of low, medium, and high doses based on grams of sugar and were 
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similar in flavor and texture.   A washout period of 10 days was implemented between 
test arms.  Symptoms were evaluated by daily diary entries with primary end points being 
addressed. 8 
The proportion of patients who answered positively to the global symptom 
question at maximal testing dose was substantially larger in the treatment arm than that of 
the other control arms high in FODMAPs.  IBS symptom severity assessed via the visual 
analogue scale also was significantly reduced within the treatment arm. This result was 
true across all symptoms evaluated. Lastly, it was seen that patients were able to maintain 
obedience to the low FODMAP diet as greater than 95% admitted to adherence. 8 See 
Figure 1.  
One limitation of this study, the authors noted, was that giving the test substances 
in liquid form may have a different physiologic response than carbohydrates provided 
within food.  Also, participants were instructed to refrain from a diet high in FODMAPs 
for 3-36 months prior to this study. It is possible that this diet altered the colonic micro-
bacteria such that the patients then hyper-reacted to introduced fermentable sugars during 
the study. Lastly, the individuals selected for inclusion were patients with IBS who had 
shown improvement in symptoms while adhering to a low FODMAP diet prior to the 
study.8 This could introduce selection bias because the individuals being observed are 
then of a particular population that are known to respond well to the intervention.  
Staudacher et al 
 This randomized control trial, 9 conducted in England, looked at IBS symptom 
severity following adherence to either a low FODMAP diet or “normal” diet.  They also 
addressed luminal microbiology via stool sampling as a surrogate outcome. The study 
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assessed 99 participants for eligibility based on a seven-day symptom severity screening. 
Of those assessed, 41 were selected and randomized to treatment or control groups. These 
participants were recruited from GI outpatient clinics and demographics were roughly 
equivalent in both groups. The median age was 35 years old and more than half were 
female. 9 
 Inclusion criteria of the study involved participants 18-65 years old with the 
diagnosis of IBS based on Rome III Criteria.  Participants were excluded if they had a 
history of other major GI conditions, had a previous GI resection or organ disorder, had 
constipation-predominant IBS, were pregnant or lactating, or had been using probiotics or 
bowel preparations within the previous 4 weeks.  The primary end point of the study was 
luminal microbiology through stool sampling and the secondary end point was effect on 
symptom severity. 9 
 After a seven day screening period in which symptom, stool, and diet evaluations 
were completed, education in and instruction to follow either a low FODMAP diet or to 
continue their normal diet was provided.  Participants were therefore not blinded to their 
allocated treatment. They were then followed over a 4-week period.  During the fourth 
and final week, they completed a daily symptom diary based on a symptom rating scale. 
The symptom scale was a 4-point system with a score of 0 indicating no symptoms and 3 
indicating severe symptoms.  They were also assessed using a global symptom question: 
“Were your symptoms adequately controlled over the previous week?” Similar stool 
screenings as done in the preliminary period were completed. 9 
 At follow up, more participants within the treatment group of a low FODMAP 
diet reported symptom control based on the global symptom question as compared to the 
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control group.  As well, more participants within the treatment group experienced a 
reduction in symptom severity scores for overall symptoms, abdominal pain, and 
bloating. Also, it was found that patients within the low FODMAP regimen were able to 
strongly adhere to this diet despite the new restrictions placed on the patients, indicating 
compliance has high potential in this population. 9 See Table 2. 
 The authors of the study did admit to limitations. Although the two groups 
received equal contact time with study conductors, the control group was not provided 
with advice for symptoms and this could have led to a placebo affect within the 
intervention group. The authors admit this could have been avoided through blinding 
with providing all food and drink to participants. Secondly, the study witnessed reduced 
luminal bacteria after this 4-week trial within the low FODMAP group. Although this 
group observed decreased symptoms, whether or not the reduced luminal bacterium has 
detrimental long-term effects on colonic health is unknown and would need to be further 
studied. 9 
Ong et al 
 This randomized, single-blinded control trial, 10 conducted in Australia, assessed 
the efficacy of a diet low in fermentable sugars within a healthy patient population as 
well as with patients diagnosed with IBS.  It was done in a crossover design in which 15 
healthy individuals and 15 individuals with IBS were randomized and blinded to 
treatment or control groups.  The IBS participants were recruited from the Functional Gut 
Disorder Clinic and the healthy participants were recruited from advertising at the local 
university.  Although the two groups were similarly high in female participants, the 
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median ages were 23 years old within the healthy group and 41 years old within the IBS 
group.10 
 The study followed inclusion and exclusion criteria for each patient population.  
For the healthy participants, they were included if they had no GI symptoms and believed 
themselves to be “healthy.”  Participants were included within the IBS group if they 
fulfilled the diagnosis of IBS based on the Rome III criteria.  All participants were 18 
years or older.  Participants were excluded if they had medically significant co-
morbidities, were pregnant, had lactose intolerance, or had used probiotics or antibiotics 
within the preceding 8 weeks.10 
 All participants consumed a high FODMAP, as well as, a low FODMAP diet for 
two-day periods with a seven-day washout period in between.  To aid in blinding, these 
diet regimens were provided to all subjects.  A seven-day baseline symptom 
questionnaire and food diary was completed prior to initiating treatment or control diets.  
Breath sample collection was also done. These evaluations were then repeated during 
both arms of the study. 10 
 Analysis of the data demonstrated that the healthy participants had a slightly 
improved symptom profile following the low FODMAP diet but this was shown to be 
statistically insignificant in most symptoms based on p values.  This indicates that healthy 
participants are less affected by dietary changes.  The participants with IBS had marked 
improvement of symptoms. This suggests that patients with IBS have a high likelihood of 
symptom improvement with a low FODMAP diet. 10 See Table 3. 
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 The authors do admit to a small sample size and suggest that larger cohorts of 
patients would need to be further studied to observe symptom profiles and effect of 
fermentable sugars. 10 
DISCUSSION 
 Providers that care for patients with IBS have utilized many treatment options 
over the years including several medications with potentially harmful side effects. These 
have often been unsuccessful as witnessed by statistics of healthcare usage by patients 
with IBS.1 This high utilization of healthcare without consistently positive outcomes may 
impede on overall satisfaction of the healthcare experience.  Uncontrolled symptoms 
result in missed workdays and decreased productivity 1 possibly resulting in a reduced 
quality of life.  Practitioners continually search for the lowest harm, yet most effective 
intervention for their patients.  This research suggests that educating patients with IBS on 
a diet low in fermentable sugars and encouraging their adherence may have meaningful 
results in their symptom severity, healthcare experience, and quality of life. All three 
studies8-10 demonstrated that a diet low in fermentable sugars effectively reduces 
symptoms in patients with irritable bowel syndrome.  Although lifestyle changes can be 
difficult to adhere to, the witnessed participants in the Shepherd et al study8 have 
seemingly followed this diet. This gives validation for a clinician to provide education for 
patients who are capable of adhering to a lifestyle modification such as this during their 
office visits. They may also recruit informed dietitians for further assistance with patient 
education. Providers have the opportunity to utilize this intervention for those individuals 
who are not interested in or have not found relief with medication treatment. Overall, the 
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findings suggest that a diet low in FODMAPs to be a potentially well-tolerated, low harm 
intervention for patients with abdominal symptoms related to IBS.   
Although these findings are promising, there are several limitations to the studies 
discussed.  Overall, small sample sizes were observed.8-10 Future research will need to 
include larger populations to truly see efficacy and any potential weaknesses of the diet.  
Two of the studies utilized a crossover design. 8,10 This structure introduces risk of bias as 
the participants are exposed to both treatment and control, possibly influencing their 
interpretation of symptoms on each diet. Although these crossover studies attempted to 
blind the participants to food profile, a crossover effect is still a possibility.  Future 
studies should avoid the crossover design.  As mentioned, blinding was attempted by two 
studies. 8,10 The Staudacher et al study9 did not make an attempt to blind participants or 
data analysts. Not having sufficient concealment can cause a performance bias, altering 
the overall results.  Although the Shepherd et al study8 made stronger efforts to blind by 
using powder drinks with similar taste profiles, the other studies9,10 made less of an effort 
with either single blinding or not blinding whatsoever. Future studies will need to utilize 
a double blinding method of introducing the treatment and control interventions to avoid 
bias.  
CONCLUSION 
 A diet low in fermentable sugars has demonstrated reduction of symptoms in 
patients with Irritable Bowel Syndrome.  Primary care providers as well as GI specialists 
can educate their patients with IBS in the diet and encourage them to adhere with little 
worry of cost or harm to the population.  Although the studies have limitations, further, 
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stronger research is needed; the benefits of this lifestyle intervention seem to outweigh 
the risks to the patient. 
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 Table 1 Characteristics of Reviewed Studies, GRADE profile 
Quality Assessment  
 Downgrade Criteria  
Study Design Limitations Indirectness Imprecision  Inconsistency Publication bias likely Quality Importance 
Shepherd   
et al8 RCT 
Serious 
limitationa 
  No 
indirectness 
Serious 
imprecisionb 
No 
inconsistency No
 Low Important 
Staudacher 
et al9 RCT 
Serious 
limitationc 
Serious 
indirectnessd 
Serious 
imprecisionb 
No 
inconsistency No
 Very low Important 
Ong et al10 RCT Very serious limitatione 
No 
indirectness 
Serious 
imprecisionb 
No 
inconsistency No Very low Important 
 
aRisk of selection bias due to Shepherd et al study selecting participants that positively respond to low FODMAP diet 
bSmall sample size 
cLack of blinding  
dUse of surrogate outcome as primary end point 
eSingle blinding and crossover effect 
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Table 2 Staudacher et al9 study: Symptom incidence and severity in patients with IBS 
following 4 weeks of treatment vs control dieta 
 Controlb Treatmentc  Controlb Treatmentc  
Symptom Incidenced (days/wk) P value Severity Scoree P value 
Bloating 5.7   
(4.9-6.4) 
3.8 
(3.0-4.6) 
0.002 1.4 
(1.2-1.6) 
0.9 
(0.6-1.1) 
0.002 
Abdominal 
pain 
4.8 
(4.1-5.5) 
3.6 
(2.8-4.4) 
0.02 1.1 
(0.9-1.4) 
0.8 
(0.5-1.1) 
0.07 
Flatulence 5.6 
(4.6-6.5) 
4.3 
(3.3-5.3) 
0.07 1.2 
(1.0-1.5) 
0.8 
(0.5-1.1) 
0.018 
Borborygmi 2.8 
(1.9-3.7) 
2.0 
(1.0-3.0) 
0.22 0.7 
(0.4-0.9) 
0.4 
(0.2-0.6) 
0.11 
Urgency 3.7 
(2.7-4.7) 
2.6 
(1.5-3.7) 
0.15 0.8 
(0.6-1.1) 
0.6 
(0.3-0.8) 
0.13 
Diarrhea 2.2 
(1.3-3.1) 
1.4 
(0.4-2.4) 
0.24 0.4 
(0.2-0.6) 
0.3 
(0.1-0.5) 
0.34 
Constipation 1.0 
(0.5-1.5) 
0.8 
(0.3-1.3) 
0.56 0.2 
(0.1-0.2) 
0.1 
(0.1-0.2) 
0.69 
Incomplete 
evacuation 
3.1 
(2.1-4.1) 
2.1 
(1.0-3.2) 
0.16 0.7 
(0.4-0.9) 
0.4 
(0.2-0.7) 
0.16 
Heartburn 0.5 
(0.0-1.1) 
0.7 
(0.0-1.3) 
0.70 0.1 
(0.0-0.2) 
0.1 
(0.0-0.2) 
0.98 
Nausea 1.8 
(0.9-2.7) 
1.5 
(0.5-2.5) 
0.67 0.4 
(0.2-0.6) 
0.3 
(0.1-0.5) 
0.64 
Tiredness 2.0 
(1.1-3.9) 
1.3 
(0.6-2.6) 
0.35 0.9 
(0.7-1.1) 
0.5 
(0.3-0.7) 
0.015 
Overall 1.6 
(1.3-1.9) 
0.9 
(0.8-1.1) 
0.001 1.7 
(1.4-1.9) 
1.1 
(0.8-1.3) 
0.002 
a Values are estimated using a 95% CI; control n=19, treatment n=16 
b Patients who continued normal diet 
c Patients who received FODMAP diet advice 
d 95% CI for number of days per week that patients experienced a symptom 
e 95% CI for severity score using the 4-point symptom severity scale 
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Table 3 Ong et al10 study: Symptom scores of IBS and healthy patients during high and 
low FODMAP diet 
Symptoms Group Number of subjects with symptom score P 
value 
RR 
value 
  Low FODMAP diet High FODMAP diet   
  0 1 2 3 0 1 2 3   
Abdominal pain Healthy 10 5 - - 6 8 1 - 0.145 1.67 IBS 6 8 1 - 2 4 7 2 0.006 3 
Abdominal 
bloating 
Healthy 10 5 - - 8 7 - - 0.484 1.25 
IBS 6 6 3 - 1 3 6 5 0.002 6 
Excessive flatus Healthy 9 5 1 - 1 6 5 3 0.007 9 IBS 6 7 1 1 - 2 7 6 0.002 0 
Nausea Healthy 13 3 - - 12 3 - - 0.773 1.08 IBS 12 3 - - 7 5 2 1 0.010 1.71 
Heartburn Healthy 13 3 - - 14 1 - - 0.424 1.45 IBS 10 5 - - 6 6 2 1 0.025 3.5 
Tiredness/lethargy Healthy 11 4 - - 10 3 2 - 0.454 1.1 IBS 9 5 1 - 4 7 1 3 0.012 2.25 
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Figure 1 Scores as Reported on the 100-mm VAS for symptoms at the end of the phase 
of the maximal dose in the Shepherd et al study.8 
Note: Results given are the median, interquartile range, and maximum and minimum 
scores. 
 
